NextCure’s (NXTC) Buy Rating Reiterated at HC Wainwright

NextCure (NASDAQ:NXTC)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $3.00 price target on the stock, down from their previous price target of $4.00. HC Wainwright’s price target indicates a potential upside of 320.82% from the company’s previous close.

NextCure Price Performance

NXTC stock opened at $0.71 on Friday. The stock has a market capitalization of $19.97 million, a price-to-earnings ratio of -0.34 and a beta of 0.71. The company has a 50-day moving average of $0.78 and a two-hundred day moving average of $1.13. NextCure has a 52-week low of $0.66 and a 52-week high of $2.57.

NextCure (NASDAQ:NXTC) last announced its earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). Equities analysts expect that NextCure will post -1.87 EPS for the current fiscal year.

Hedge Funds Weigh In On NextCure

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC grew its position in NextCure by 40.6% in the 4th quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock worth $61,000 after purchasing an additional 22,724 shares during the last quarter. Geode Capital Management LLC grew its position in NextCure by 14.2% during the third quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock worth $307,000 after buying an additional 27,812 shares in the last quarter. Tang Capital Management LLC increased its stake in NextCure by 7.3% during the fourth quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock valued at $540,000 after acquiring an additional 47,614 shares during the period. Renaissance Technologies LLC raised its holdings in NextCure by 27.9% in the 4th quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock valued at $400,000 after acquiring an additional 113,300 shares in the last quarter. Finally, Peapod Lane Capital LLC bought a new stake in shares of NextCure in the 4th quarter worth approximately $311,000. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.